|
|
|
| Effect of Shenmai Injection on microvascular density and quality of life of hepatic carcinoma patients with arterial infusion chemotherapy |
| WANG Bo1 WANG Youqing1 MAO Kui1▲ CHEN Long1 SUN Weijian2 |
1.Department of General Surgery, First People's Hospital of Linhai City, Zhejiang Province, Linhai 317000, China;
2.Department of General Surgery, Second Affiliated Hospital of Wenzhou Medical University, Zhejiang Province,Wenzhou 325000, China |
|
|
|
Abstract Objective To explore the effect of Shenmai Injection on microvascular density and quality of life of hepatic carcinoma(HCC) patients with arterial infusion chemotherapy. Methods From January 2015 to January 2017, in the First People's Hospital of Linhai City and the Second Affiliated Hospital of Wenzhou Medical University, 90 HCC patients treated with arterial infusion chemotherapy were collected, according to random number table method, patients were divided into control group and observation group, with 45 cases in each group, all patients were treated with arterial perfusion chemotherapy, the observation group was given Shenmai injection on the basis of the control group, immunohistochemical expression of VEGF and MVD were analyzed, and the quality of life was evaluated. Results The positive staining was not uniform of VEGF and MVD in the two groups, and the control group was darker, and the observation group was shallower. The expression of VEGF and MVD in HCC in the observation group was significantly lower than that in the control group, and the differences were statistically significant (P < 0.01). The overall quality of life of the observation group was better than that of the control group, the difference was statistically significant (P < 0.05). Conclusion Shenmai Injection can obviously improve the prognosis of hepatic carcinoma patients with arterial infusion chemotherapy, effectively restrain VEGF expression of the liver tissue, reduce the density of blood vessels and MVD, thereby inhibit tumor angiogenesis, improve the quality of life, which is worth promoting.
|
|
|
|
|
|
[1] Grierson P，Crites D，Ruzinova MB，et al. Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab：A case report of late response after pseudoprogression [J]. Hepatol Commun，2017，2（2）：148-151.
[2] Adams P，Howlett C，Xenocostas A，et al. Sex-specific analysis post-liver transplantation in hemochromatosis with aplastic anemia and hepatocellular carcinoma [J]. Hepatol Commun，2017，2（1）：13-15.
[3] Szpakowski JL，Drasin TE，Lyon LL. Rate of seeding with biopsies and ablations of hepatocellular carcinoma： A retrospective cohort study [J]. Hepatol Commun， 2017，1（9）：841-851.
[4] Hamanaka M，Noda M，Imada A，et al. Two cases of achieving a pathological complete response via hepatic arterial infusion chemotherapy for liver-limited and unresectable liver metastases from colorectal cancer with RAS mutations [J]. Gan To Kagaku Ryoho，2017，44（12）：1329-1331.
[5] 梁宏元.原发性肝癌综合介入治疗现状与困惑[J].临床肝胆病杂志，2016，32（1）：44-48.
[6] 杜文杰，刘祖炳，刘华生.原发性肝癌介入治疗中经导管肝动脉栓塞与肝动脉灌注化疗栓塞的远期疗效比较[J].中华肿瘤防治杂志，2016，23（S2）：167-171.
[7] 余健，辛艳飞，宣尧仙，等.参麦注射液药理作用的物质基础研究进展[J].医药导报，2013，32（4）：497-500.
[8] 周雍明.参麦注射液联合化疗对肺恶性肿瘤气阴两虚证患者免疫功能及生活质量的影响[J].中国全科医学，2015，（32）：3969-3972.
[9] Han K，Kim JH. Transarterial chemoembolization in hepatocellular carcinoma treatment： Barcelona clinic liver cancer staging system [J]. World J Gastroenterol，2015，21（36）：10327-10335.
[10] 万崇华.生命质量测定与评价方法[M].昆明：云南大学出版社，1999.
[11] Nakano M，Niizeki T，Nagamatsu H，et al. Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib，for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread： A prospective cohort study [J]. Mol Clin Oncol，2017，7（6）：1013-1020.
[12] Gong Q，Qin Z，Hou F. Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation [J]. Oncol Lett，2017，14（6）：7045-7048.
[13] Tu J，Ying X，Zhang D，et al. High expression of angiogenic factor AGGF1 is an independent prognostic factor for hepatocellular carcinoma [J]. Oncotarget，2017，8（67）：111 623-111 630.
[14] Luo LM，Xia H，Shi R，et al. The association between aquaporin-1 expression，microvessel density and the clinicopathological features of hepatocellular carcinoma [J]. Oncol Lett，2017，14（6）：7077-7084.
[15] Qu Z，Jiang Y，Xu M，et al. Correlation of adrenomedullin with the erythropoietin receptor and microvessel density in hepatocellular carcinoma [J]. Arch Med Sci，2015，11（5）：978-981.
[16] Mohamed A，Chenna A，Abdelfatah M，et al. Microvessel density analysis in patients with viral hepatitis-related hepatocellular carcinoma [J]. J Gastrointest Cancer，2015， 46（2）：104-108.
[17] 胡哲源，朱超，江华，等.重组人内皮抑素联合顺铂化疗对恶性黑色素瘤MVD及VEGF的影响探究[J].中国生化药物杂志，2014，34（9）：30-32.
[18] 樊涛，韩琴芳，曹冬花，等.多层螺旋CT肺癌灌注成像与VEGF表达和MVD的关系[J].实用放射学杂志，2014， （4）：617-619，678.
[19] Müller K，Karrer S，Szeimies RM，et al. Beurteilung der Lebensqualität bei Patienten mit nicht-melanozytärem Hautkrebs - psychometrische Validierung des EORTC QLQ-C30-Fragebogens [J]. J Dtsch Dermatol Ges，2017， 15（11）：1090-1102.
[20] Velenik V，Secerov-Ermenc A，But-Hadzic J，et al. Health-related Quality of Life Assessed by the EORTC QLQ-C30 questionnaire in the general slovenian population [J]. Radiol Oncol，2017，51（3）：342-350.
[21] Koller M，Hjermstad MJ，Tomaszewski KA，et al. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients [J]. Ann Oncol，2017，28（11）：2874-2881.
[22] 宋慧娴，乔飞，邵铭.中医药治疗原发性肝癌的研究进展[J].临床肝胆病杂志，2016，32（1）：174-177. |
|
|
|
